Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Journal
The Lancet Oncology
Journal Volume
22
Journal Issue
8
Pages
1126-1138
Date Issued
2021
Author(s)
Brose M.S.
Robinson B.
Sherman S.I.
Krajewska J.
Vaisman F.
Hoff A.O.
Hitre E.
Bowles D.W.
Hernando J.
Faoro L.
Banerjee K.
Oliver J.W.
Keam B.
Capdevila J.
SDGs
Publisher
Lancet Publishing Group
Type
journal article